Hadassah

Hadassah-Pluristem Trial Approved for Placental Cell Bone Marrow Regeneration

Monday, Feb 22 2016

The Federal Drug Administration (FDA) has approved the start of a Phase I trial with a placental-cell based therapy to mitigate acute radiation syndrome (ARS) and enhance bone marrow regeneration following a bone marrow transplant. The product, PLX-R18, was developed by Pluristem Therapeutics based on studies of Prof. Raphael Gorodetsky, head of Hadassah’s Biotechnology and Radiobiology Laboratories at the Sharett Institute of Oncology.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery).

Prof. Gorodetsky and his colleagues helped Pluristem to identify the potency of the new cell product, having conducted an extensive preclinical study at Hadassah. The preclinical findings with PLX-R18 cells (also termed PLX-RAD) were initially published in PLOS-ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066549) by Prof. Raphael Gorodetsky and the development team, and they were further verified at the National Institutes of Health (NIH) and other prominent centers in the United States. The new cell product’s mechanism of action was also explored in collaboration with the Charité Univeristy Medical Center in Berlin, where its researchers revealed that PLX-R18 cells secrete a wide range of specific proteins which could trigger the resurgence of the necessary early descendants of stem cells (progenitor cells) that can differentiate to form one or more kinds of cell and support the regeneration of all blood cell lineages.

The preclinical studies paved the way for PLX-R18’s application as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy. “PLX-R18-based therapy,” notes Prof. Gorodetsky, “may present a breakthrough in the lifesaving treatment of acute radiation syndrome, which so far has had very limited alternative treatments. It can be anticipated that this cell therapy may serve also as a safe and easy treatment for a variety of severe hematopoietic disorders.”

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Oct 15 2018

Hadassah Dedicates Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem News Release

Hadassah unveiled the Irma and Paul Milstein Heart Center at Hadassah Hospital Ein Kerem on Friday, October 12th in Jerusalem, announced Ellen Hershkin, National President, Hadassah, the Women’s Zionist Organization of America, Inc.

READ MORE ›
alt_text

Friday, Oct 12 2018

New Zealand Scholarship Winner Comes to Hadassah Hospital

Describing it as a “life-changing experience,” Dinithi Seneviratne, a New Zealand health care professional, recently spent several weeks as an observer in the Pediatric Emergency Department at Hadassah Hospital in Ein Kerem, Jerusalem.

READ MORE ›
alt_text

Thursday, Oct 4 2018

Hadassah Receives $4.75M Grant from Helmsley Charitable Trust to Expand New Pediatric Bone Marrow Transplant (BMT) Unit

The Helmsley Charitable Trust has awarded a $4.75M grant to the Hadassah Medical Organization (HMO) in Israel to expand its Pediatric Bone Marrow Transplant (BMT) Unit, announced Ellen Hershkin, National President, Hadassah, The Women’s Zionist Organization of America, Inc. (HWZOA).

READ MORE ›
alt_text

Friday, Sep 28 2018

Hadassah Saves Mom and Delivers Her Baby in the Intensive Care Unit

A 32-year-old Palestinian woman in her third trimester of pregnancy developed blood clots and bruises and began to feel weak. Her local physicians were puzzled and recommended that she consult experts at the Hadassah Medical Organization in Jerusalem.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More